摘要
目的比较阿霉素载药微球TACE(DEB-TACE)与传统的碘化油TACE(cTACE)治疗原发性肝细胞癌(HCC)的近期疗效。方法计算机检索中国期刊全文数据库、中国生物医学文献数据库、中文科技期刊全文数据库、PubMed、CochraneLibrary、EMBASE,检索日期为2000年12月—2013年6月有关DEB-TACE与cTACE治疗HCC的随机对照试验(RCT)文献,依据Jadad评价手册评价文献质量。根据纳入和排除标准筛选文献。对纳入文献提取原始数据,采用RevManManager 5.1软件进行Meta分析,计算合并OR值及95%可信区间(95%CI)。结果最终纳入8篇文献,共885例患者。Meta分析结果显示:完全缓解[OR:1.67,95%CI(1.21,2.31),P=0.10];部分缓解[OR:1.16,95%CI(0.85,1.60),P=0.90];病变稳定[OR:0.70,95%CI(0.45,1.07),P=0.17];6个月生存率[OR:1.62,95%CI(0.82,3.21),P=0.96];12个月生存率[OR:1.65,95%CI(1.04,2.61),P=0.74]。结论 DEB-TACE与cTACE对于治疗HCC的近期疗效差异无统计学意义,但能提高1年生存期。
Objective To compare the short-term effect of the Doxorubicin-eluting Beads chemoembolization（DEB-TACE）with the conventional TACE（cTACE）in hepatocellular carcinoma（HCC）.Methods PubMed,Medline,Embase,the Chinese BioMedical Literature and the China Nationl Knowledge Infrastructure were searched for randomized controlled trails comparing DEB-TACE and cTACE for treatment of HCC from December 2000 to June 2013.Meta-analysis was performed using RevMan Manager 5.1software from the Jadad collaboration.Pooled odds ratios（ORs）with 95%CIs were calculated.Results Totally 8randomized controlled trials comprising 885 patients treated by cTACE versus DEB-TACE for HCC were enrolled.Meta analysis showed that：Complete response[OR：1.67,95%CI[1.21,2.31],P=0.10];partial response[OR：1.16,95%CI[0.85,1.60],P=0.90];stable disease[OR：0.70,95%CI[0.45,1.07],P=0.17];Median overall survival（Mos）of 6months[OR：1.62,95%CI[0.82,3.21],P=0.96];Mos of 12months[OR：1.65,95%CI[1.04,2.61],P=0.74].Conclution Compared to cTACE,the short-term efficacy of DEB-TACE has no difference,but can provide a higher 1-year survival rate.
出处
《中国介入影像与治疗学》
CSCD
2014年第11期712-716,共5页
Chinese Journal of Interventional Imaging and Therapy
